Navigation Links
Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
Date:10/23/2008

SAN CARLOS, Calif., Oct 23 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2008 on Thursday, November 6, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com.

To access the conference call, follow these instructions:

Dial: 866.362.4666 (U.S.); 617.597.5313 (international)

Participant Passcode: 63756947 (Howard Robin is the host)

An audio replay will also be available shortly after the call and will remain so through November 20, 2008.

To access the replay, follow these instructions:

Dial: 888-286-8010 (U.S.); 617-801-6888 (international)

Participant Passcode: 41304675

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and conjugate chemistry technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

Contact:

Stephan Herrera, 415-488-7699

sherrera@nektar.com

Jennifer Ruddock, 650-631-4954

jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar Therapeutics Announces Second Quarter 2008 Results
2. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
3. Nektar Therapeutics Announces First Quarter 2008 Results
4. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
5. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
8. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
9. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
10. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
11. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed ... of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada ... Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that ...
(Date:7/21/2017)... MO (PRWEB) , ... July 21, 2017 , ... “Kids ... knowing how to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive ... Time-In Toolkit, which launches on Kickstarter on Monday, July 21st. , The kit ...
(Date:7/21/2017)... ... July 21, 2017 , ... The ... offer patients improved quality of life five years after injury, according to research ... Meeting in Toronto, Ontario, Canada. The study followed patients for five years following ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... of blood and bone marrow cancer that progresses rapidly without treatment. Newly diagnosed ... to reduce the chance of reoccurrence and relapse. With such a challenging ...
(Date:7/20/2017)... New York (PRWEB) , ... July 20, 2017 ... ... has developed a telemedicine platform, in which their iMedSecure™ comes included with each ... both share encrypted live images to remote participants for real-time collaboration and immediate ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... , July 10, 2017  US medical equipment and ... 2021, according to Medical Equipment & Supplies: ... Freedonia Focus Reports. Continued increases in demand for medical ... of the population and supported by gains in disposable ... and supplies. New product introductions will also drive sales ...
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
(Date:7/5/2017)... 2017 Wolfmet 3D  printed tungsten collimator manufactured by M&I ... manufacturing combine to progress molecular radiotherapy imaging. In ... unable to accurately quantify the radiation absorbed by those patients ... success of this radiotherapy treatment has been available — that ... ...
Breaking Medicine Technology: